Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management

To assess the pattern of hypertension in the population in terms of presence of additional risk factors (ARF) and cardiovascular risk stratification.

Study Overview

• Status: Completed
• Conditions: Hypertension
• Intervention / Treatment: Other: Usual Care

Detailed Description

routine physician visits

• Study Type: Observational
• Enrollment (Actual): 899

Contacts and Locations

Study Locations

• Croatia
  • Varazdin, Croatia, 42000
    • Pfizer Investigational Site
• Czechia
  • Prague 4, Czechia, 140 00
    • Pfizer Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Adult Hypertensive Patients managed in primary care

Description

Inclusion Criteria:

• Age 18 to 80 years old
• Patients with hypertension: newly diagnosed and /or already diagnosed and treated , whether at goal or not for the blood pressure level;
• Patients with no history of CHD/CVD

Exclusion Criteria:

• None

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Hypertensive Subjects undergoing primary prevention	Other: Usual Care; Normal care for hypertensive patients with risk factors for CHD

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Description of hypertensive patients in terms of presence of associated cardiovascular (CV) risk factors (number of additional CV risk factors and frequency)

Secondary Outcome Measures

Outcome Measure
Description of pattern of management of HT and CVD prevention, through lifestyle and use of drug therapies,
Estimate adherence to treatment using the Morisky Adherence Scale (MAS)
Estimation of hypertensive patients CV risk stratification based on ESH/ESC Hypertension Guidelines 2007 and to compare it with physicians' estimation of CV risk.

Collaborators and Investigators

• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Study record dates

Study Major Dates

• Study Start: June 1, 2008
• Primary Completion (Actual): February 1, 2009
• Study Completion (Actual): February 1, 2009

Study Registration Dates

• First Submitted: July 1, 2008
• First Submitted That Met QC Criteria: July 1, 2008
• First Posted (Estimate): July 3, 2008

Study Record Updates

• Last Update Posted (Actual): January 27, 2021
• Last Update Submitted That Met QC Criteria: January 26, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Keywords: Epidemiology, hypertension, risk factors, coronary heart disease, patient management, compliance with medication
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Hypertension
• Other Study ID Numbers: A3841059